Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973872 | 0.91 | CYP2D6 (0.42) | ACEGAA | |
| SCHEMBL915196 | 0.81 | IDO1 (0.54) | IDO1RECQLALDH1A1GAAACHE | |
| SCHEMBL11711886 | 0.81 | CYP2D6 (0.53) | ACEIDO1RECQLALDH1A1GAA | |
| SCHEMBL8257896 | 0.81 | ACE (0.48) | ACEIDO1KMT2AALDH1A1BCHE | |
| SCHEMBL9906029 | 0.80 | ACE (0.46) | ACEPPARGPPARA | |
| Ammonia Solution, Strong SCHEMBL7247404 | 0.79 | CYP2D6 (0.56) | ACEIDO1MEN1KMT2AALDH1A1 | |
| SCHEMBL18313729 | 0.79 | TSHR (0.38) | ACEIDO1GAAPPARGPPARA | |
| SCHEMBL8260553 | 0.79 | SLC6A4 (0.50) | ACE | |
| SCHEMBL18313733 | 0.79 | ACE (0.38) | ACEHTT | |
| SCHEMBL22856970 | 0.78 | GAA (0.52) | ACEIDO1ALDH1A1GAAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | BRITISH COLUMBIA CANCER AGENCY BRANCH | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | KLK3, FOLH1, FOLR1 | ACE 4292/4885IDO1 4110/4885RECQL 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.